Hypoattenuating leaflet thickening diagnosed within 24 hours following percutaneous pulmonary valve implantation was successfully resolved with systemic anticoagulation therapy.
Case Report (n=1)
Does anticoagulation resolve acute hypoattenuating leaflet thickening (HALT) following percutaneous pulmonary valve implantation (PPVI) in a patient with repaired Tetralogy of Fallot?
Acute hypoattenuating leaflet thickening (HALT) can occur very early after percutaneous pulmonary valve implantation and may be successfully managed with oral anticoagulation.
Background: Hypoattenuating leaflet thickening (HALT) is a reported complication following percutaneous pulmonary valve implantation (PPVI) Case description: A 32-year-old man with a history of repaired Tetralogy of Fallot (TOF) underwent PPVI for symptomatic severe pulmonary regurgitation (PR). The postoperative course was complicated by HALT diagnosed by computed tomography (CT) within 24 h of the procedure. Anticoagulation therapy was administered, and reassessment CT at 4 months showed resolution of HALT. Conclusion: HALT following PPVI is managed with anticoagulation yet consensus for optimal management strategy is lacking.
Lee et al. (Thu,) conducted a case report in Hypoattenuating leaflet thickening (HALT) after percutaneous pulmonary valve implantation (n=1). Anticoagulation (heparin followed by apixaban) was evaluated on Resolution of hypoattenuating leaflet thickening. Hypoattenuating leaflet thickening diagnosed within 24 hours following percutaneous pulmonary valve implantation was successfully resolved with systemic anticoagulation therapy.